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(Lee et al., 2006) tive and reflect genetic etiology when available and ac-
commodate the spectrum of phenotypic variation. Cli-
nicians and scientists must value the nomenclature’s
use, and it must be understandabl to patients and their
families. An example of how the proposed nomenclature
could be applied in a classification of DSD is shown in
Table 2.
Psychosexual development is traditionally conceptu-
alized as 3 components: “gender identity” refers to a
person’s self-representation as male or female (with the
caveat that some individuals may not identify exclu-
sively with either); “gender role” (sex-typical behaviors)
describes the psychological characteristics that are sexu-
ally dimorphic within the general population, such as
toy preferences and physical aggression; and “sexual
orientation” refers to the direction(s) of erotic interest
(heterosexual, bisexual, homosexual) and includes be-
havior, fantasies, and attractions. Psychosexual develop-
ment is influenced by multiple factors such as exposure
to androgens, sex chromosome genes, and brain struc-
ture, as well as social circumstance and family dynamics.
Gender dissatisfaction denotes unhappiness with as-
signed sex. Causes of gender dissatisfaction, even among
individuals without DSD, are poorly understood. Gender
dissatisfaction occurs more frequently in individuals
with DSD than in the general population but is difficult
to predict from karyotype, prenatal androgen exposure,
degree of genital virilization, or assigned gender.5–7 Pre-
natal androgen exposure is clearly associated with other
aspects of psychosexual development.8,9 There are dose-
related effects on childhood play behavior in girls with
congenital adrenal hyperplasia (CAH), whereby those
with the more severe mutations and marked genital
virilization play more with boys’ toys.10 Prenatal andro-
gen exposure is also associated with other psychological
characteristics such as maternal interest and sexual ori-
entation. It is important to emphasize the separability of
sex-typical behavior, sexual orientation, and gender
identity. Thus, homosexual orientation (relative to sex
of rearing) or strong cross-sex interest in an individual
with DSD is not an indication of incorrect gender assign-
ment. Understanding variations in psychosexual devel-
opment in individuals with DSD requires reference to
studies in nonhuman species that show marked but
complex effects of androgens on sex differentiation of
the brain and on behavior. Outcomes can be influenced
by the timing, dose, and type of androgen exposure,
receptor availability, and modification by the social en-
vironment.11–14
Data from rodent studies suggest that sex chromo-
some genes may also influence brain structure and be-
havior directly.15,16 However, studies in individuals with
complete androgen insensitivity syndrome (CAIS) do
not indicate a behavioral role for Y-chromosome genes,
although data are limited.17 Sex differences in brain
structures have been identified across species, some of
which coincide with pubertal onset, perhaps suggesting
hormonal responsivity.18–20 The limbic system and hypo-
thalamus, both of which play a role in reproduction,
show sex differences in specific nuclei, but it is not clear
TABLE 1 Proposed Revised Nomenclature
Previous Proposed
Intersex DSD
Male pseudohermaphrodite, undervirilization of




of an XX female, and masculinization of an
XX female
46,XX DSD
True hermaphrodite Ovotesticular DSD
XX male or XX sex reversal 46,XX testicular DSD
XY sex reversal 46,XY complete
gonadal dysgenesis
TABLE 2 An Example of a DSD Classification
Sex Chromosome DSD 46,XY DSD 46,XX DSD
45,X (Turner syndrome and variants) Disorders of gonadal (testicular) development: (1)
complete gonadal dysgenesis (Swyer
syndrome); (2) partial gonadal dysgenesis; (3)
gonadal regression; and (4) ovotesticular DSD
Disorders of gonadal (ovarian) development: (1)
ovotesticular DSD; (2) testicular DSD (eg, SRY!,
duplicate SOX9); and (3) gonadal dysgenesis
47,XXY (Klinefelter syndrome and variants) Disorders in androgen synthesis or action: (1)
androgen biosynthesis defect (eg, 17-
hydroxysteroid dehydrogenase deficiency,
5!RD2 deficiency, StAR mutations); (2) defect
in androgen action (eg, CAIS, PAIS); (3)
luteinizing hormone receptor defects (eg,
Leydig cell hypoplasia, aplasia); and (4)
disorders of anti-Müllerian hormone and anti-
Müllerian hormone receptor (persistent
Müllerian duct syndrome)
Androgen excess: (1) fetal (eg, 21-hydroxylase
deficiency, 11-hydroxylase deficiency); (2)
fetoplacental (aromatase deficiency, POR "P450
oxidoreductase#); and (3) maternal (luteoma,
exogenous, etc)
45,X/46,XY (MGD, ovotesticular DSD) Other (eg, cloacal exstrophy, vaginal atresia,
MURCS "Müllerian, renal, cervicothoracic somite
abnormalities#, other syndromes)
46,XX/46,XY (chimeric, ovotesticular DSD)
Although consideration of karyotype is useful for classification, unnecessary reference to karyotype should be avoided; ideally, a system based on descriptive terms (eg, androgen insensitivity
syndrome) should be used wherever possible. StAR indicates steroidogenic acute regulatory protein.
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 Joosten /DeFuentes-Merillas /de Weert /
Sensky /van der Staak /de Jong 
Psychother Psychosom 2008;77:219–226220
and legislation has been passed in several countries aimed 
at strengthening the influence of patients  [5] .
 One method of fostering these modern priorities of 
the clinician-patient relationship is through the process 
of shared decision-making (SDM). SDM is defined as an 
approach in which the clinician and patient go through 
all phases of the decision-making process together and in 
which they share the preference for treatment and reach 
an agreement on treatment choice  [2, 6–8] . Forms of de-
cision-making can be regarded as a continuum with two 
extremes – the ‘traditional medical model’ and the ‘in-
formed medical model’  [2, 9, 10] .  Table 1 de onstrates 
where SDM fits between these extremes. 
 Charles et al.  [11] have identified necessary criteria for 
or characteristics of SDM. The first characteristic is that 
SDM involves clinician and patient. Often the treatment 
decision involves more than one patient and one clini-
cian. The involvement of family members in treatment 
decision-making may be important. Furthermore, steps 
are taken to ensure that clinician and patient are both in-
volved in the pr cess of decision-making. Additionally, 
both parties take steps to build a consensus about the pre-
ferred treat ent. At t e very least, the clinician needs to 
explain the treatment alternatives and their possible con-
sequences for the patient. The patient and clinician both 
bring information and values into their discussion. Fi-
nally, the patient and clinician together discuss and eval-
uate treatment options and together build a consensus on 
the treatment to implement. 
 Frequently, SDM studies comprise the use of decision 
aids. Decision aids are interventions designed to help 
people make specific and deliberative choices among op-
tions by providing relevant information about the op-
tions and outcomes relevant to a person’s health status 
 [12] . A systematic review of decision aids concluded that 
they improve patients’ knowledge regarding treatment 
options and their condition  [12] . Decision aids appear to 
have no effect on satisfaction with decision-making, anx-
iety, and health outcomes.
 Published SDM studies have reported improvements 
in patient sa isfaction, treatment adherence, quality of 
life and well-being  [13] when clinicians adopt a patient-
centred approach  [14] and when patients are more in-
volved and perceive greater control over their treatment 
choice  [11, 15–17] . SDM should foster a patient-centred 
approach and empower patients, therefore the outcomes 
mentioned above are appropriate to use in assessing the 
effectiveness of SDM. The aim of the present systematic 
review was to examine the extent, quality and consisten-
cy of the published res arch evidence for the effectiveness 
of SDM with respect to these outcome variables.
 Method 
 Inclusion and Exclusion Criteria 
 The review included studies that met all the following criteria: 
(1) studies in which a treatment decision needed to be made; (2) 
randomised controlled trial design; (3) involving patients aged 18 
Table 1. Models of shared decision-making about treatment [2, 42]
Paternalistic model
(‘traditional medical model’)
Shared decision-making ‘Informed medical model’
Role of the 
clinician
Active: Reports only selected 
information to the patient, 
chooses the therapy he 
 considers best for the patient.
Active: Reports all information and 
 treatment possibilities to the patient.
Can recommend an option. Decides on 
the therapy together with the patient.
Passive: Reports all information and 
treatment possibilities to the patient. 
Withholds his recommendations. 
Makes no decision.
Role of the 
patient
Passive: Accepts the proposal 
of the clinician. Is obliged to 
cooperate in his recovery.
Active: Receives all information. Forms 
his own judgement on harms and benefits 
of treatment options. Discusses his
preferences with the clinician. Decides
on the therapy together with the clinician.
Active: Receives all information. 
Forms his own judgement.
Is free to choose between all options 
unbiased by his clinicians’ own option.
Decides on the therapy alone.





Clinician ] patient 




Patient (plus potential others)
Who decides? Clinician Clinician and patient Patient
(Joosten et al., 2008) 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DECISION‐AID FOR PARENTS OF CHILDREN WITH DSD 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